June 5, 2019
Astellas Pharma said on June 3 that its investigational antibody-drug conjugate (ADC) enfortumab vedotin achieved an objective response rate of 44% in a PII study in patients with locally advanced or metastatic urothelial cancer. The PII study called EV-201 was...read more